ABSTRACT
Introduction
Initially described by Erasmus Wilson in 1896, lichen planus is a relatively common chronic skin disease and one of the most common oral mucosal diseases. [1] It is an autoimmune skin and mucosal disorder mediated by T-lymphocytes. [2] Some studies have shown that oral lichen planus (OLP) has the potential to develop to oral squamous cell carcinoma (OSCC). [3] [4] [5] However, the relation between OLP and OSCC is even now controversial since many researchers believe that still there is not enough data to prove the correlation between OLP and occurrence of cancer. [6] OSCC comprises approximately 90% of oral cancers and is the eleventh most common cancer of human, showing an increased inci-dence. Despite the current improvements in the treatment of this disease, OSCC still has a high mortality rate and its 5-year survival rate is 45-50%. OSCC has different etiological factors; nonetheless, no single causative factor is clearly defined or accepted. [1, [3] [4] 6] A cancer occurs when mutation or amplification causes dysregulation of the genes that control the cell cycle. [7] The main targets of genetic damage that leads to cancer are four groups of the normal cell cycle regulatory genes; including 1-proto-oncogenes, which accelerate the growth, 2-tumor suppressor or growth inhibitor genes, 3-genes that regulate the apoptosis, and 4-genes that are involved in DNA repair. [7] Abnormalities in oncogenes and tumor suppressor genes have been detected in oral carcinoma. [1] Different stages of cell cycle are controlled and conducted by cyclins, cyclindependent kinases (CDK), and their inhibitors. [7] [8] p21 protein is a potent CDK inhibitor belonging to the tumor suppressor genes. It binds to CDK and inhibits the RB (retinoblastoma) phosphorylation and the activity of the CDK2 and CDK4 complex which is essential for the cells to enter G1phase. Therefore, it is recognized as a regulator of cell-cycle progression in G1 phase. [7] [8] The gene mutations that involve the CDK complex are identified in some malignant neoplasms and are likely to act in favor of cell proliferation process. [7] Only few studies have evaluated and compared the immunostaining of proteins (such as p21) that control the cell cycle in OLP and OSCC. This study was aimed to evaluate and compare the incidence of p21 (as a proliferation inhibitory factor) in OLP and OSCC.
Materials and Method
The samples of this descriptive -analytic study were All the samples were reviewed by a pathologist concerning the criteria described in the related articles. The slides were then rinsed with PBS and distilled water respectively for 2 minutes. Hematoxylin staining was performed within 5 minutes; the slides were then placed in lithium carbonate for 2 minutes and then rinsed with tap water for 5 minutes. The slides were soaked in 96% and 100% alcohol and xylene for 5 minutes; the samples were then mounted. The stained slides were studied under 100 x and 400 x light microscope (Olympus CX31; Tokyo, Japan). They were compared with the positive control sample (melanoma) to verify the accurate staining.
The cells with brown-stained nucleus (with any intensity) were considered as positively stained cells. In each slide, a total of 1000 cells were counted (under 400 The spearman correlation coefficient was calculated to be 0.736 (p< 0.001). In each group, the results are summarized in Table 2 . The mean percentages of p21-positive cells of SCC (54.5±6.6) ( Figure 1 ) were considerably higher than OLP (32.8±6.08) ( Figure 2 ) and OEH (9.4±3.8) (Figure 3 ). (Table 3) . considered it as a potentially malignant disorder. [14] However, the relation between OLP and OSCC is still controversial. [1, 6] In the current study positive p21
staining was observed in all specimens of OSCC and mean percentage of stained cells in OSCC was 54.5%; which was significantly higher than the two other groups (OLP 32.8% and OEH 9.4%). Also, the staining intensity in OSCC was higher than the other groups. In the study performed by Yanamoto et al., they evaluated p21 expression in OSCC and reported that 53% of the samples showed p21 staining. [18] However, it seems that the p21 staining level is different in human malignancies. For instance, p21 protein expression or p21 mRNA has been detected in SCC of skin, carcinomas of the lungs, cancers of head and neck, and hepatocellular carcinoma while it has been reduced in colorectal and ovarian carcinoma. [18] The differences in the expression of p21, detected in various malignancies, could not be associated with alterations in genes since p21 gene mutation was not observed in many malignancies. [19] p21 binds to a collection of cyclins and CDKs that are effective in cell cycle progression and disables them. The binding affinity of p21 to CDK will increase if it is accompanied by cyclin. [20] Also the inhibitory function of CDKs and p21 are reported to be set stoichiometrically; it causes p21 to activate or deactivate CDKs. [21] According to the previously published studies, p21 is not a permanent CDK inhibitor and it rather affects G1 regulatory cyclins selectively. [20] On the other side, if the proliferating cells are in G1 phase, cell growth would be stopped with low levels of p21; however, if the cells are in synthesis phase (S) they will continue to proliferate until p21 reaches the sufficient level.
Thus, in malignancies p21, by itself, is not probably enough to inhibit CDK activity completely and stop the cell growth. [23, [25] [26] increased staining of p21 in OLP is likely to show inactivity of its cell-cycle inhibiting role, which in turn might be the initial genetic event in carcinogenesis. [19] The increased staining of p21 in dysplastic lesions that are transforming to carcinomas has been reported by González-Moles et al., [26] although some reports consider this increase in the p21 expression as a response to hyper proliferative condition. [23, 26] The results of the current study revealed that among the study groups, the mean age of patients with OSCC was higher than the patients of the other two groups. Also a significant statistical correlation was observed between age and the mean percentages of p21 + cells; this result is in line with the results of the study conducted by Ng et al. [17] They reported a significant relation between p21 expression in OSCC samples and the patients' age; the older the patients were the more likely to express p21. In the present study, no statistically significant relation was detected among p21 expression, the location of the lesions, and the patients' gender; which was consistent with the studies carried out by
Ng et al. and Yanamoto et al. [17] [18] Regarding the considerable staining of OLP compared to the OEH, and also based on the results of the present and previous studies, oral lichen planus might be considered among the inflammatory diseases that have the potential to progress to carcinoma. [22, 24] In future studies, evaluating the association of p21 with other cell-cycle regulators may confirm the results of the current study.
Conclusion
According to the findings of this study, the expression of p21 might be related to the potential carcinogenic transformation of lichen planus to SCC. Follow-up periods are recommended for early diagnosis of the malignant transformations in lichen planus.
